Iturbide A, Ruiz Tejada Segura ML, Noll C, Schorpp K, Rothenaigner I, Ruiz-Morales ER, et al. Retinoic acid signaling is critical during the totipotency window in early mammalian development. Nat Struct Mol Biol. 2021;28:521–32.
Google Scholar
Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ. Regulation of human hematopoietic stem cell self-renewal by the microenvironment’s control of retinoic acid signaling. Proc Natl Acad Sci USA. 2013;110:16121–6.
Google Scholar
Mishra S, Kelly KK, Rumian NL, Siegenthaler JA. Retinoic acid is required for neural stem and progenitor cell proliferation in the adult Hippocampus. Stem Cell Rep. 2018;10:1705–20.
Google Scholar
Makimoto A, Fujisaki H, Matsumoto K, Takahashi Y, Cho Y, Morikawa Y, et al. Retinoid therapy for neuroblastoma: historical overview, regulatory challenges, and prospects. Cancers. 2024;16:3.
Google Scholar
Szymański Ł, Schenk T, Ławiński M, Brioli A, Zelent A. Association of retinoids, retinoic acid receptors and epigenetics in breast cancer. Oncogene. 2026;45:961–70.
Google Scholar
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun. 2020;11:4841.
Google Scholar
Schenk T, Stengel S, Zelent A. Unlocking the potential of retinoic acid in anticancer therapy. Br J Cancer. 2014;111:2039–45.
Google Scholar
van Gils N, Verhagen H, Smit L. Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation. Exp Hematol. 2017;52:12–23.
Google Scholar
D’Ambrosio DN, Clugston RD, Blaner WS. Vitamin A metabolism: an update. Nutrients. 2011;3:63–103.
Google Scholar
Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med. 2006;203:1283–93.
Google Scholar
Purton LE. Roles of retinoids and retinoic Acid receptors in the regulation of hematopoietic stem cell self-renewal and differentiation. PPAR Res. 2007;2007:87934.
Google Scholar
Kirkham JK, Liu YC, Foy SG, Ma J, Gheorghe G, Furtado LV, et al. Clinical and genomic characterization of an ATRA-insensitive acute promyelocytic leukemia variant with a FNDC3B::RARB fusion. Genes Chromosomes Cancer. 2023;62:617–23.
Google Scholar
Jiang M, Li J, Wu J, Zhu Y, Gao J. Case report: A rare case of TBL1XR1-RARB positive acute promyelocytic leukemia in child and review of the literature. Front Oncol. 2022;12:1028089.
Google Scholar
Cabezas-Wallscheid N, Buettner F, Sommerkamp P, Klimmeck D, Ladel L, Thalheimer FB, et al. Vitamin A-Retinoic acid signaling regulates hematopoietic stem cell dormancy. Cell. 2017;169:807–23.e19.
Google Scholar
Cho CJ, Brown JW, Mills JC. Origins of cancer: ain’t it just mature cells misbehaving? EMBO J. 2024;43:2530–51.
Google Scholar
Ruijtenberg S, van den Heuvel S. Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle. 2016;15:196–212.
Google Scholar
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.
Google Scholar
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
Google Scholar
Sbirkov Y, Schenk T, Kwok C, Stengel S, Brown R, Brown G, et al. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells. Front Cell Dev Biol. 2023;11:1076458.
Google Scholar
Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res. 1971;31:127–34.
Google Scholar
Schubert D, Humphreys S, Jacob F, de Vitry F. Induced differentiation of a neuroblastoma. Dev Biol. 1971;25:514–46.
Google Scholar
Lotem J, Sachs L. In vivo control of differentiation of myeloid leukemic cells by recombinant granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood. 1988;71:375–82.
Google Scholar
Huang ME, Ye YC, Chen SR, Zhao JC, Gu LJ, Cai JR, et al. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J. 1987;100:949–53.
Google Scholar
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133:1630–43.
Google Scholar
Mengeling BJ, Phan TQ, Goodson ML, Privalsky ML. Aberrant corepressor interactions implicated in PML-RAR(alpha) and PLZF-RAR(alpha) leukemogenesis reflect an altered recruitment and release of specific NCoR and SMRT splice variants. J Biol Chem. 2011;286:4236–47.
Google Scholar
Zhou J, Pérès L, Honoré N, Nasr R, Zhu J, de Thé H. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA. 2006;103:9238–43.
Google Scholar
Villiers W, Kelly A, He X, Kaufman-Cook J, Elbasir A, Bensmail H, et al. Multi-omics and machine learning reveal context-specific gene regulatory activities of PML::RARA in acute promyelocytic leukemia. Nat Commun. 2023;14:724.
Google Scholar
Nguyen CH, Grandits AM, Purton LE, Sill H, Wieser R. All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells. Cell Cycle. 2020;19:2573–88.
Google Scholar
Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605–11.
Google Scholar
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–67.
Google Scholar
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920–4.
Google Scholar
Stomper J, Rotondo JC, Greve G, Lübbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35:1873–89.
Google Scholar
Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in higher-risk MDS patients compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. Blood. 2007;110:817.
Google Scholar
Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, et al. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. Am J Hematol. 2015;90:E139–41.
Google Scholar
Momparler RL, Doré BT, Momparler LF. Effect of 5-aza-2’-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett. 1990;54:21–8.
Google Scholar
Wang L, Zhang Q, Ye L, Ye X, Yang W, Zhang H, et al. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex. Br J Cancer. 2023;128:691–701.
Google Scholar
Meier R, Greve G, Zimmer D, Bresser H, Berberich B, Langova R, et al. The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation. Blood Cancer J. 2022;12:122.
Google Scholar
Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y, et al. All-trans retinoic acid combined with 5-Aza-2’-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res Commun. 2012;428:216–23.
Google Scholar
Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, et al. Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. Haematologica. 2026;111:1683–93.
Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21:473–87.
Google Scholar
Watts JM, Bradley TJ, Thomassen A, Dinh YT, Tejera D, Englund K, et al. The Lysine-Specific Demethylase 1 (LSD1) Inhibitor Tranylcypromine (TCP) in combination with ATRA is tolerable and has anti-leukemic activity in adult patients with relapsed/refractory AML and MDS. Blood. 2018;132:2721.
Google Scholar
Ross DM, Stevenson WS, Shortt J, Cooney J, Lewis I, Rienhoff HY Jr. Phase 1/2a Trial of Bomedemstat with or without All- Trans Retinoic Acid (ATRA) in Advanced Myeloid Malignancies. Blood. 2023;142:6494.
Google Scholar
Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, et al. A proof of concept Phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia. 2021;35:701–11.
Google Scholar
Kruszewski M, Schmoor C, Berg T, Rehman UU, Schittenhelm M, Götze K, et al. Sensitization of Non-M3 acute myeloid leukemia blasts to all-trans retinoic acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study. Eur J Haematol. 2025;115:266–77.
Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, et al. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia. 2019;33:2628–39.
Google Scholar
Ghazvini Zadegan F, Stanko C, Fiedler F, Olsner L, Ozcan SG, Schutt J, et al. Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression. BMC Cancer. 2026;26.
Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123:207–18.
Google Scholar
Kühn MW, Song E, Feng Z, Sinha A, Chen CW, Deshpande AJ, et al. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. Cancer Discov. 2016;6:1166–81.
Google Scholar
Perner F, Gadrey JY, Armstrong SA, Kühn MWM. Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions. Int J Cancer. 2026;158:342–56.
Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, et al. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024;38:2073–84.
Google Scholar
Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146:1065–77.
Google Scholar
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, Phase 1 trial. Lancet Oncol. 2024;25:1310–24.
Google Scholar
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation 2024 [updated 15.11.2024. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation.
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation 2025 [updated 24.10.2025. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation.
Bourgeois W, Cutler J, Rice HE, Regalado B, Wenge DV, Perner F, et al. Discerning the landscape of menin inhibitor resistance. Blood. 2024;144:724.
Google Scholar
Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913–9.
Google Scholar
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, et al. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023;108:2837–43.
Google Scholar
Fleischmann M, Bechwar J, Voigtländer D, Fischer M, Schnetzke U, Hochhaus A, et al. Synergistic effects of the RARalpha agonist Tamibarotene and the Menin Inhibitor Revumenib in acute myeloid leukemia cells with KMT2A rearrangement or NPM1 mutation. Cancers. 2024;16:7.
Google Scholar
Yi Y, Ge S. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias. J Hematol Oncol. 2022;15:35.
Google Scholar
Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011;117:6912–22.
Google Scholar
Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013;121:2533–41.
Google Scholar
Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122:1017–25.
Google Scholar
Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661–9.
Google Scholar
Perner F, Gadrey JY, Xiong Y, Hatton C, Eschle BK, Weiss A, et al. Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts. Blood. 2020;136:1983–8.
Google Scholar
Al-Khallaf H. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight. Cell Biosci. 2017;7:37.
Google Scholar
Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010;16:387–97.
Google Scholar
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.
Google Scholar
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621–5.
Google Scholar
DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90:732–6.
Google Scholar
Gunn K, Myllykoski M, Cao JZ, Ahmed M, Huang B, Rouaisnel B, et al. R)-2-Hydroxyglutarate inhibits KDM5 Histone Lysine Demethylases to drive transformation in IDH-mutant cancers. Cancer Discov. 2023;13:1478–97.
Google Scholar
Lang F, Kaur K, Fu H, Zaheer J, Ribeiro DL, Aladjem MI, et al. D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming. Nat Commun. 2025;16:1431.
Google Scholar
Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. Leukemia. 2024;38:927–35.
Google Scholar
McMurry H, Fletcher L, Traer E. IDH Inhibitors in AML-Promise and Pitfalls. Curr Hematol Malign Rep. 2021;16:207–17.
Google Scholar
Amatangelo MD, Quek L, Shih A, Stein EM, Roshal M, David MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732–41.
Google Scholar
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–31.
Google Scholar
Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622–6.
Google Scholar
Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016;213:483–97.
Google Scholar
Kim Y, Jeung HK, Cheong JW, Song J, Bae SH, Lee JI, et al. All-Trans Retinoic acid synergizes with Enasidenib to induce differentiation of IDH2-mutant acute myeloid leukemia cells. Yonsei Med J. 2020;61:762–73.
Google Scholar
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66.
Google Scholar
Kasbekar M, Mitchell CA, Proven MA, Passegué E. Hematopoietic stem cells through the ages: a lifetime of adaptation to organismal demands. Cell Stem Cell. 2023;30:1403–20.
Google Scholar
Nakamura-Ishizu A, Takizawa H, Suda T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development. 2014;141:4656–66.
Google Scholar
Worker A, Jinks N, Woodmancy P, Seedhouse C, Kellaway SG. How to drug a leukemic stem cell: deciphering heterogeneity for better specificity. Blood Neoplasia. 2025;2:100146.
Google Scholar
Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M, et al. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2:508–28.
Google Scholar
Hu XT, Zuckerman KS. Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells. Cell Prolif. 2014;47:200–10.
Google Scholar
Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015;125:90–101.
Google Scholar
Uras IZ, Sexl V, Kollmann K. CDK6 inhibition: a novel approach in AML management. Int J Mol Sci. 2020;21:7.
Google Scholar
Chen D, Law ME, Theis JD, Gamez JD, Caron LB, Vrana JA, et al. Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. Am J Surg Pathol. 2009;33:720–9.
Google Scholar
Hayette S, Tigaud I, Callet-Bauchu E, Ffrench M, Gazzo S, Wahbi K, et al. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood. 2003;102:1549–50.
Google Scholar
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124:13–23.
Google Scholar
Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, et al. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016;127:2890–902.
Google Scholar
Tan HN, Curigliano G, Yap TA. Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies. Trends Cancer. 2026;12:553–68.
Qu W, Lu J, Ji Y, He Z, Hou M, Li D, et al. Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia. Cancer Chemother Pharmacol. 2024;94:635–9.
Google Scholar
Yang J, Friedman R. Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia. Cancer Cell Int. 2023;23:161.
Google Scholar
Skopek R, Özcan SG, Chmiel P, Morgner S, Schütt J, Ghazvini et al. Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML. Br J Haematol. 2025;207:1279–88.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease: Current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097–154.
Google Scholar
Kist M, Vucic D. Cell death pathways: intricate connections and disease implications. EMBO J. 2021;40:e106700.
Google Scholar
Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112:957–62.
Google Scholar
Zhou JD, Zhang TJ, Xu ZJ, Gu Y, Ma JC, Li XX, et al. BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia. Diagn Pathol. 2019;14:68.
Google Scholar
Krawiec K, Strzałka P, Czemerska M, Wiśnik A, Zawlik I, Wierzbowska A, et al. Targeting Apoptosis in AML: where do we stand? Cancers. 2022;14:20.
Google Scholar
Killock D. Venetoclax in AML: efficacy confirmed. Nat Rev Clin Oncol. 2020;17:592.
Google Scholar
Pisani F, Del Poeta G, Aronica G, Venditti A, Caravita T, Amadori S. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Ann Hematol. 1997;75:145–7.
Google Scholar
Li D, Li H, Cheng C, Li G, Yuan F, Mi R, et al. All-trans retinoic acid enhanced the antileukemic efficacy of ABT-199 in acute myeloid leukemia by downregulating the expression of S100A8. Int Immunopharmacol. 2022;112:109182.
Google Scholar
Jing J, Nelson C, Paik J, Shirasaka Y, Amory JK, Isoherranen N. Physiologically based Pharmacokinetic model of all-trans-retinoic acid with application to cancer populations and drug interactions. J Pharmacol Exp Ther. 2017;361:246–58.
Google Scholar
Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307:1101–4.
Google Scholar
Campbell CJ, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B, et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 2010;116:1433–42.
Google Scholar
Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120–5.
Google Scholar
Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep. 2013;2:12–4.
Google Scholar
Wang R, Xia L, Gabrilove J, Waxman S, Jing Y. Sorafenib inhibition of Mcl-1 Accelerates ATRA-induced apoptosis in differentiation-responsive AML cells. Clin Cancer Res. 2016;22:1211–21.
Google Scholar
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O’Brien S, et al. A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clin Cancer Res. 2024;30:4844–55.
Google Scholar
Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med. 2023;3:154.
Google Scholar
Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280:35217–27.
Google Scholar
Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther 2015;3:2.
Google Scholar
Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154–64.
Google Scholar
Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, et al. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opin Ther Targets. 2018;22:639–53.
Google Scholar
Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102:972–80.
Google Scholar
Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. The PI3K-Akt-mTOR Signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21:8.
Google Scholar
Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, et al. A Phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res. 2009;15:6732–9.
Google Scholar
Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010;16:5424–35.
Google Scholar
Lang F, Wunderle L, Badura S, Schleyer E, Brüggemann M, Serve H, et al. A Phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacol Toxicol. 2020;21:70.
Google Scholar
Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2015;29:828–38.
Google Scholar
Stengel S, Petrie KR, Sbirkov Y, Stanko C, Ghazvini Zadegan F, Gil V, et al. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia. Br J Haematol. 2022;198:338–48.
Google Scholar
Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood. 2002;99:2199–206.
Google Scholar
Xu C, Kim NG, Gumbiner BM. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle. 2009;8:4032–9.
Google Scholar
Duan Y, Liu Z, Wang Q, Zhang J, Liu J, Zhang Z, et al. Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology. Genes Dis. 2025;12:101435.
Google Scholar
Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood. 2009;114:1618–27.
Google Scholar
Dobrevski B, Willems H, Lossius-Cott C, Müller JP. Targeting oncogenic activity and signalling of mutant receptor tyrosine Kinase FLT3. Cancers. 2025;17:17.
Google Scholar
Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6:e8.
Google Scholar
Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.
Google Scholar
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907–14.
Google Scholar
Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res. 2003;9:2140–50.
Google Scholar
Wierenga AT, Schepers H, Moore MA, Vellenga E, Schuringa JJ. STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBPalpha. Blood. 2006;107:4326–33.
Google Scholar
Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood. 2004;103:1883–90.
Google Scholar
Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, et al. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015;29:535–47.
Google Scholar
Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE, et al. A review of FLT3 Kinase inhibitors in AML. J Clin Med. 2023;12:6429.
Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120:4205–14.
Google Scholar
Sung PJ, Selvam M, Riedel SS, Xie HM, Bryant K, Manning B, et al. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. Leukemia. 2024;38:291–301.
Google Scholar
Scholl S, Müller R, Clement JH, Loncarevic IF, Böhmer FD, Höffken K. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells. Leuk Res. 2006;30:633–42.
Google Scholar
Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, et al. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood. 2016;127:2867–78.
Google Scholar
Sánchez-Mendoza SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, Machado-Neto JA, Djavaheri-Mergny M, et al. All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations. Ann Hematol. 2024;103:5405–16.
Google Scholar
Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567–72.
Google Scholar
Küley-Bagheri Y, Kreuzer KA, Monsef I, Lübbert M, Skoetz N. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)). Cochrane Database Syst Rev. 2018;8:Cd011960.
Google Scholar
Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, et al. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Ann Hematol. 2016;95:1931–42.
Google Scholar
Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2020;38:257–70.
Google Scholar
Ozeki M, Shively JE. Differential cell fates induced by all-trans retinoic acid-treated HL-60 human leukemia cells. J Leukoc Biol. 2008;84:769–79.
Google Scholar
Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708–20.
Google Scholar
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, et al. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023;141:1610–25.
Google Scholar
Mosialou I, Ali AM, Labella R, Bisikirska B, Cuesta-Dominguez A, Vgenopoulou P, et al. A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies. Cancer Cell. 2025;43:1007–24.e13.
Google Scholar
Cavalu S, Abdelhamid AM, Saber S, Elmorsy EA, Hamad RS, Abdel-Reheim MA, et al. Cell cycle machinery in oncology: A comprehensive review of therapeutic targets. FASEB J. 2024;38:e23734.
Google Scholar
